Ending Soon! Save 33% on All Access

Medicinal Cannabis Startup Cannarma Raises Funding To Diversify Product Line The capital was raised from Zero to One Fund at pre-money Valuation of $2.04 million

By Entrepreneur Staff

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Unsplash

Medicinal Cannabis startup Cannarma, incubated in Amity Innovation Incubator (Amity University), and recognized by the Startup India, has announced that it has raised an undisclosed amount from Zero to One Fund at pre-money valuation of ₹ 17 crore ($2.04 million).

The startup plans to use the funds for several growth initiatives including deeper engagement with existing customers, expansion into new geographies, building technology, expand presence in over 10,000+ Medical Stores, Clinics, and Hospitals across India. The company is also preparing itself to be ready for entering the global market by the next financial year, and is working on new product development for effective targeted therapeutics.

Founded by Rohit Chauhan and Keshav Agarwal in August 2022, Cannarma works towards providinge therapeutic values of medicinal properties of cannabis which were neglected in world since long. India is one of the most recognized and highly regarded Medical Cannabis/Hemp brands, operating in a market with a total addressable size of over $146.4 Billion, it says.

Thus, the company is taking the prime mover advantage when the whole world, including India, is shifting to Alternate Medicine and Natural Products. Speaking on the fundraise, Chauhan, founder, Cannarma said, "We are delighted to receive this funding from Zero to One Fund which will enable us to expand our net level of growth in the country and prepare ourselves for global expansion next year."

Praveen Kaushik, Director of Zero To One Fund, said, "The investment in Cannarma shows our commitment to back ideas which are not only disruptive but also with sustainable future profits. As the world gears up towards alternative medicines, returning to human knowledge that has been ignored by science for centuries, the horizon of treatment using cannabis phytocannabinoids is growing wider and wider. The Cannabis plant, one among the five sacred plants in Ayurveda known as "Vijaya", is having deep therapeutic values and had been used in healing chronic illness in olden times. The time is not far when Cannabis will attain its past glory and will be healing the world again, thanks to startups like Cannarma."

Entrepreneur Staff

Entrepreneur Staff

Editor

For more than 30 years, Entrepreneur has set the course for success for millions of entrepreneurs and small business owners. We'll teach you the secrets of the winners and give you exactly what you need to lay the groundwork for success.
Side Hustle

The Side Hustle He Started at Age 15 Led to a $4 Billion Boon for Small Businesses: 'They Would Take a Chance on Me With Their Hard-Earned Money'

Nic Beique asked his local barber, gym and more if they'd like him to build a website for their businesses.

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Business News

Now that OpenAI's Superalignment Team Has Been Disbanded, Who's Preventing AI from Going Rogue?

We spoke to an AI expert who says safety and innovation are not separate things that must be balanced; they go hand in hand.

Starting a Business

I Wish I Knew These Four Things Before Starting My Own Business

Starting a business is hard work to say the least. These are four lessons I wish someone had shared with me before going solo, so I'm here to share them with you.

Employee Experience & Recruiting

Beyond the Great Resignation — How to Attract Freelancers and Independent Talent Back to Traditional Work

Discussing the recent workplace exit of employees in search of more meaningful work and ways companies can attract that talent back.

Franchise

What Franchising Can Teach The NFL About The Impact of Private Equity

The NFL is smart to take a thoughtful approach before approving institutional capital's investment in teams.